Deucrictibant (PHA-022121)

DRUG5 trials

Sponsors

Pharvaris Netherlands B.V.

Conditions

Acquired Angioedema due to C1 Inhibitor DeficiencyHereditary AngioedemaHereditary angioedema

Phase 2

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema

RecruitingCTIS2023-505766-28-00

Pharvaris Netherlands B.V.Hereditary angioedema

Start: 2022-10-10Target: 74Updated: 2025-10-29

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.

CompletedCTIS2023-507268-37-00

Pharvaris Netherlands B.V.Hereditary Angioedema

Start: 2024-07-29End: 2025-10-15Target: 73Updated: 2025-09-16

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

RecruitingCTIS2024-516247-62-00

Pharvaris Netherlands B.V.Hereditary Angioedema

Start: 2025-03-10Target: 37Updated: 2025-10-10

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

RecruitingCTIS2024-516248-24-00

Pharvaris Netherlands B.V.Hereditary Angioedema

Start: 2025-03-28Target: 78Updated: 2025-09-10

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency

Not yet recruitingCTIS2025-522051-26-00

Pharvaris Netherlands B.V.Acquired Angioedema due to C1 Inhibitor Deficiency

Target: 9Updated: 2026-03-18